Open Access

Expression and significance of PTEN and Claudin‑3 in prostate cancer

  • Authors:
    • Xinglong Ye
    • Lijing Zhao
    • Jing Kang
  • View Affiliations

  • Published online on: April 3, 2019     https://doi.org/10.3892/ol.2019.10212
  • Pages: 5628-5634
  • Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Expression and significance of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and Claudin‑3 in the blood of patients with prostate cancer [prostate cancer (PCa)] were investigated. Retrospective analysis of 84 cases of PCa patients confirmed by pathological diagnosis were studied, as the experiment group. Moreover, the physical examination data of 84 healthy volunteers examined in the Affiliated Hospital of Beihua University were the control group. The expression levels of blood in the PTEN and Claudin‑3 of both the experiment group and the control group were determined by enzyme‑linked immunosorbent assay. According to the blood expression in PTEN and Claudin‑3 between both the experiment group and the control group, the test value of the ROC curve in PTEN and Claudin‑3 were detected by both single detection and joint detection. The expression levels of PTEN in the experiment group were significantly lower than the control group (P<0.05). The expression levels of Claudin‑3 were higher in the experiment group than the control group (P<0.01). The expression levels of PTEN and Claudin‑3 in the experiment group were significantly associated with the distant metastasis of cancer cells, preoperative prostate‑specific antigen levels, tumor diameter and pathological stages (P<0.01). The expression levels of PTEN in the pathological stage of T1‑T2 group was lower than that of the T3‑T4 group (P<0.01). The expression levels of PTEN and Claudin‑3 are closely related to the distant metastasis of cancer cells, preoperative prostate-specific antigen level, tumor diameter and pathological stage. Combined detection of both PTEN and Claudin‑3 can improve the specificity levels of PCa for diagnosis and has an important diagnostic value for PCa. It can be used as a biological indicator for PCa diagnosis, disease severity analysis and efficacy evaluation.

References

1 

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al: Integrative clinical genomics of advanced prostate cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Song W and Jeon HG: Incidence of kidney, bladder, and prostate cancers in Korea: An update. Korean J Urol. 56:422–428. 2015. View Article : Google Scholar : PubMed/NCBI

3 

De Nunzio C, Albisinni S, Freedland SJ, Miano L, Cindolo L, Finazzi Agrò E, Autorino R, De Sio M, Schips L and Tubaro A: Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: A prospective multicenter Italian cohort study. Urol Oncol. 31:997–1002. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Krupski TL, Stukenborg GJ, Moon K and Theodorescu D: The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer. BJU Int. 106:1477–1483. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Liu L, Tian Z, Zhang Z and Fei B: Computer-aided detection of prostate cancer with MRI: Technology and applications. Acad Radiol. 23:1024–1046. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Koval M: Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol. 75:551–567. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, Fendrich V, Ring J, Sipos B, Tuveson DA, et al: Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut. 62:1034–1043. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Mosley M, Knight J, Neesse A, Michl P, Iezzi M, Kersemans V and Cornelissen B: Claudin-4 SPECT imaging allows detection of aplastic lesions in a mouse model of breast cancer. J Nucl Med. 56:745–751. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Bezdekova M, Brychtova S, Sedlakova E, Langova K, Brychta T and Belej K: Analysis of Snail-1, E-cadherin and claudin-1 expression in colorectal adenomas and carcinomas. Int J Mol Sci. 13:1632–1643. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Li JY, Xie F, Xu XP, Ma JJ, Zhou DC, Liao Y, Tang J, Xie Q, Bai L and Nan QZ: Claudin-3 expression in colorectal carcinoma and its significance. Nan Fang Yi Ke Da Xue Xue Bao. 37:63–67. 2017.(In Chinese). PubMed/NCBI

11 

Jones N, Bonnet F, Sfar S, Lafitte M, Lafon D, Sierankowski G, Brouste V, Banneau G, Tunon de Lara C, Debled M, et al: Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer. 133:323–334. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Zhang Y, Feng J, Fu H, Liu C, Yu Z, Sun Y, She X, Li P, Zhao C, Liu Y, et al: Coagulation factor X regulated by CASC2c recruited macrophages and induced M2 polarization in glioblastoma multiforme. Front Immunol. 9:15572018. View Article : Google Scholar : PubMed/NCBI

13 

Wise HM, Hermida MA and Leslie NR: Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 131:197–210. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Zhang LL, Liu J, Lei S, Zhang J, Zhou W and Yu HG: PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression. Cell Signal. 26:1011–1020. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Huang J, Yuan SX, Wang DX, Wu QX, Wang X, Pi CJ, Zou X, Chen L, Ying LJ, Wu K, et al: The role of COX-2 in mediating the effect of PTEN on BMP9 induced osteogenic differentiation in mouse embryonic fibroblasts. Biomaterials. 35:9649–9659. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Yu M, Mu Y, Qi Y, Qin S, Qiu Y, Cui R and Zhong M: Odontogenic ameloblast-associated protein (ODAM) inhibits human colorectal cancer growth by promoting PTEN elevation and inactivating PI3K/AKT signaling. Biomed Pharmacother. 84:601–607. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K and Sofras F: Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 78:313–317. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Albert RH and Clark MM: Cancer screening in the older patient. Am Fam Physician. 78:1369–1374. 2008.PubMed/NCBI

19 

Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, Froemming AT, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, et al Expert Panel on Urologic Imaging, : ACR Appropriateness criteria® prostate cancer-pretreatment detection, surveillance and staging. J Am Coll Radiol. 14:S245–S257. 2017. View Article : Google Scholar : PubMed/NCBI

20 

Bailey DE Jr and Wallace M: Critical review: Is watchful waiting a viable management option for older men with prostate cancer? Am J Men Health. 1:18–28. 2007. View Article : Google Scholar

21 

de Oliveira Barros EG, Palumbo A Jr, Mello PL, de Mattos RM, da Silva JH, Pontes B, Viana NB, do Amaral RF, Lima FR, da Costa NM, et al: The reciprocal interactions between astrocytes and prostate cancer cells represent an early event associated with brain metastasis. Clin Exp Metastasis. 31:461–474. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Sinibaldi VJ: Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. Clin Interv Aging. 2:555–560. 2007. View Article : Google Scholar : PubMed/NCBI

23 

Yokoyama M, Narita T, Sakurai H, Katsumata-Kato O, Sugiya H and Fujita-Yoshigaki J: Maintenance of claudin-3 expression and the barrier functions of intercellular junctions in parotid acinar cells via the inhibition of Src signaling. Arch Oral Biol. 81:141–150. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Yang XD, Zhao SF, Zhang Q, Li W, Wang YX, Hong XW and Hu QG: PTEN gene polymorphisms and susceptibility to oral squamous cell carcinoma in a Chinese Han population. Tumour Biol. 37:577–582. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Yang Y, Guo JX and Shao ZQ: miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. Asian Pac J Trop Med. 10:87–91. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, Cheng L, Masterson TA, Liu X, Ratliff TL, et al: Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab. 19:393–406. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Chinni SR, Li Y, Upadhyay S, Koppolu PK and Sarkar FH: Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 20:2927–2936. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Phattarataratip E and Sappayatosok K: Expression of claudin-5, claudin-7 and occludin in oral squamous cell carcinoma and their clinico-pathological significance. J Clin Exp Dent. 8:e299–e306. 2016.PubMed/NCBI

29 

Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P and Preusser M: Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 36:844–850. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ye, X., Zhao, L., & Kang, J. (2019). Expression and significance of PTEN and Claudin‑3 in prostate cancer. Oncology Letters, 17, 5628-5634. https://doi.org/10.3892/ol.2019.10212
MLA
Ye, X., Zhao, L., Kang, J."Expression and significance of PTEN and Claudin‑3 in prostate cancer". Oncology Letters 17.6 (2019): 5628-5634.
Chicago
Ye, X., Zhao, L., Kang, J."Expression and significance of PTEN and Claudin‑3 in prostate cancer". Oncology Letters 17, no. 6 (2019): 5628-5634. https://doi.org/10.3892/ol.2019.10212